SCHEMBL4919616

SCHEMBL4919616

CS(=O)(=O)Nc1cccc(Nc2nc(N3CCOCC3)c3nc[nH]c3n2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 3/20 0.57
PIK3CG P48736 1/20 0.57
CHEK1 O14757 7/20 0.54
LMNA P02545 2/20 0.48
CYP1A2 P05177 2/20 0.48
CYP3A4 P08684 2/20 0.48
TSHR P16473 1/20 0.48
RECQL P46063 1/20 0.48
USP2 O75604 1/20 0.48
MAPK1 P28482 1/20 0.48
HIF1A Q16665 1/20 0.48
CLK4 Q9HAZ1 1/20 0.48
PTK2 Q05397 1/20 0.48
MTOR P42345 2/20 0.48
JAK2 O60674 3/20 0.46
JAK3 P52333 2/20 0.46
ZAP70 P43403 1/20 0.46
SYK P43405 1/20 0.46
BRD4 O60885 1/20 0.44
MAPT P10636 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4917022 0.91 PIK3CA (0.46) PIK3CAPIK3CGCHEK1LMNACYP1A2
SCHEMBL4914681 0.89 BRD4 (0.53) PIK3CAPIK3CGLMNACYP1A2CYP3A4
SCHEMBL4920489 0.88 BRD4 (0.48) PIK3CAPIK3CGCHEK1CYP1A2CYP3A4
SCHEMBL4438221 0.85 PIK3CA (0.75) PIK3CAPIK3CGLMNACYP1A2CYP3A4
SCHEMBL4917631 0.83 PTK2 (0.47) PIK3CAPIK3CGPTK2JAK2JAK3
SCHEMBL4910485 0.81 CYP1A2 (0.54) PIK3CAPIK3CGCYP1A2CYP3A4USP2
SCHEMBL4917865 0.80 PTK2 (0.38) PIK3CAPIK3CGCHEK1LMNACYP1A2
SCHEMBL4917337 0.80 PTK2 (0.40) PIK3CAPIK3CGCHEK1CYP1A2CYP3A4
SCHEMBL4916441 0.79 PTK2 (0.38) PIK3CAPIK3CGCHEK1LMNACYP1A2
SCHEMBL4649832 0.78 PTK2 (0.50) CYP1A2CYP3A4TSHRUSP2CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080261973-A1 Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors NOVARTIS AG (CH) 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261973-A1 Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors GRK4, JAK2, ALK PIK3CA 635/4885PIK3CG 1751/4885CHEK1 1488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.